Last week, one of China’s largest vaccine makers, Changchun Changsheng Biotechnology, was exposed...
- Realm Therapeutics unveils phase II failure of PR022 for severe eczema
- Janssen and ViiV report positive results for two drug regimen for HIV-1
- Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth
- PhRMA survey shows US biopharma exceeded R&D spending record in 2017
- The road to market: breaking down the stages of clinical trials for pharmaceutical products
Boehringer Ingelheim’s Integrated Asian Veterinary R&D Centre, Shanghai
Germany-based pharmaceutical company Boehringer Ingelheim’s veterinary research and development (R&D) centre is located within its R&D plant site in Shanghai, China.
So you want to break into the Chinese vaccine market?
Last week, one of China’s largest vaccine makers, Changchun Changsheng Biotechnology, was exposed for selling and distributing hundreds of thousands of faulty vaccines for children.
Revlimid demonstrates positive phase III results in Indolent NHL
Celgene has announced positive new data for its leading blockbuster drug, Revlimid (lenalidomide), which earned revenues of $8.2bn in 2017.
Fasinumab Phase III osteoarthritis trial meets endpoints
Teva Pharmaceutical and Regeneron Pharmaceuticals have reported positive top-line data from a phase III clinical trial of fasinumab to treat chronic pain in patients with osteoarthritis (OA) of the knee or hip.
EMA gives PRIME status to promising Huntington’s treatment
PRIME is the European Medicines Agency (EMA) Priority Medicines scheme to support the development of medicines that meet a high unmet need.
UK seeks harmony with EU CTR as NHS and pharma stockpile drugs
The Medicines Health Products Regulatory Agency has reaffirmed its commitment to follow the European Clinical Trials Regulation System (CTR) during the Brexit transition period, between March 2019 and December 2020.
Realm Therapeutics unveils phase II failure of PR022 for severe eczema
US-based Realm Therapeutics has announced its drug candidate PR022 for atopic dermatitis has failed to achieve its primary endpoint in a phase II trial.
Janssen and ViiV report positive results for two drug regimen for HIV-1
Johnson & Johnson subsidiary Janseen Pharmaceuticals and ViiV Healthcare have reported positive topline results from their phase III trial of an investigational long-acting injectable two drug regimen for the treatment of human immunodeficiency virus-1 (HIV-1).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.